Browse the evidence

Higher maximum semaglutide dose was associated with lower post-landmark risk of all-cause mortality (RR 0.42, p<0.001) and composite cardiovascular events (RR 0.51, p<0.001).

Practitioners should consider maximizing semaglutide dosage to enhance cardiovascular outcomes.

Semaglutide was associated with lower cardiovascular events than metformin, DPP-4 and SGLT2 inhibitors.

Semaglutide may be a preferable option for patients at risk of cardiovascular events compared to other medications.

1-year treatment persistence among individuals without diabetes initiating high-potency, weight loss-indicated GLP-1RA products increased from 33.2% in 2021 to 60.9% in 1H 2024.

Practitioners should note the significant improvement in treatment persistence, which may indicate better patient adherence and management strategies.

Semaglutide 1-year persistence rates increased from 33.2% in 2021 to 58.6% in 1H 2024.

The increase in semaglutide persistence suggests improved patient adherence, which may be beneficial for weight management strategies.

Tirzepatide 1-year persistence rates were 64.0% in 2023 and 64.8% in 1H 2024.

The high persistence rates for tirzepatide indicate its potential effectiveness and acceptance among patients for weight management.

GLP-1 receptor agonists (GLP-1RAs) have substantial new evidence supporting their use in managing endocrine disorders.

Clinicians should consider the new evidence on GLP-1RAs for managing various endocrine disorders.

A thorough preoperative evaluation is essential to optimize outcomes and minimize risks for body contouring procedures after significant weight loss.

Practitioners should ensure thorough evaluations before body contouring surgeries.

Semaglutide represents a practice-changing therapy that addresses core pathophysiological drivers of ASCVD and HFpEF through integrated modulation of adiposity and metabolic dysfunction.

Clinicians should consider semaglutide as a key treatment option for managing ASCVD and HFpEF.

Liraglutide treatment improved glycaemia as indicated by decreased C-peptide levels.

Liraglutide may help improve blood sugar levels in patients with type 2 diabetes.

Antiobesity medications require long-term use to prevent weight regain.

Practitioners should emphasize the importance of ongoing medication adherence for effective weight management.

Community-based lifestyle interventions to manage excess weight can be successfully conducted in Indigenous Australians, but with generally limited efficacy.

Practitioners should consider implementing community-based lifestyle programs, while being aware of their limited effectiveness.

The effect of lifestyle programs on weight reduction was modest (∼2-4 kg after 4-12 months).

Weight loss from lifestyle programs may be limited, and practitioners should set realistic expectations.

GLP-1 receptor agonists show promising results in men, improving erectile function, testosterone levels, and sperm parameters.

Practitioners may consider GLP-1 receptor agonists as a potential treatment option for men experiencing erectile dysfunction.

Tirzepatide achieves unprecedented weight loss, but case reports suggest potential sexual side effects.

Clinicians should monitor for potential sexual side effects in patients using Tirzepatide for weight loss.

There is a risk of excessive reduction in skeletal muscle mass (SMM) with GLP-1-based therapies.

Practitioners should monitor muscle mass in patients using GLP-1 therapies to mitigate risks of sarcopenia.

GLP-1 receptor agonists enhance insulin secretion, support weight loss, and exhibit neuroprotective and cardiovascular benefits.

Practitioners can consider GLP-1 receptor agonists for their multifaceted benefits in diabetes management.

Use of incretin-based therapies (IBT) after bariatric surgery is associated with a 55% lower risk of new-onset alcohol use disorder (AUD) compared to non-IBT antiobesity medications (AOMs).

Practitioners may consider prescribing IBT for patients post-bariatric surgery to reduce the risk of AUD.

IBT is associated with a 41% lower risk of initiation of medications for alcohol use disorder (MAUDs) compared to non-IBT AOMs.

IBT may be a beneficial option for reducing the need for MAUDs in post-bariatric surgery patients.

Non-Hispanic Black (NHB) participants had lower percent total weight loss (%TWL) at 3, 12, and 24 months compared with Hispanic (H) and non-Hispanic White (NHW) participants.

Healthcare providers should consider racial and ethnic differences when evaluating weight loss outcomes post-surgery.

GLP-1RA use was associated with a lower risk of major adverse cardiovascular events (MACE) in nondiabetic patients with PAD (HR: 0.61; 95% CI: 0.57–0.66; p < 0.001).

GLP-1RAs may be beneficial for reducing cardiovascular risks in patients with PAD who do not have diabetes.

Tirzepatide helps lower blood sugar levels in patients with type 2 diabetes mellitus.

Tirzepatide can be considered for managing blood sugar levels in type 2 diabetes.

Metabolic and bariatric surgery (MBS) is the most effective long-term treatment for severe obesity and its associated comorbidities.

MBS should be considered as a primary treatment option for patients with severe obesity.

MBS is associated with improved glycemic and metabolic control, lower apnea burden, reduced risk of major adverse cardiovascular events, and improved overall survival.

MBS can significantly improve health outcomes for patients with severe obesity.

GLP-1 receptor agonists reduced major adverse cardiovascular events (MACE) by 31% in Asians.

GLP-1RAs may provide significant cardiovascular benefits for Asian populations.